[{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"PENAO Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"PENAO","moa":"||AdNT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Aurigene Pharmaceutical Services \/ PENAO Pty Ltd"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A (AURKA)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VITRAC Therapeutics \/ University of Minnesota","highestDevelopmentStatusID":"7","companyTruncated":"VITRAC Therapeutics \/ University of Minnesota"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"National Human Genome Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sio Gene Therapies \/ National Human Genome Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ National Human Genome Research Institute"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Series C Financing","leadProduct":"Rapamycin","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Umoja Biopharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Double Point Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Umoja Biopharma \/ Double Point Ventures"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Aucta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Aucta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aucta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ CPRIT"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Insight | Biodexa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Insight | Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Cancer Insight | Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ CPRIT","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ CPRIT"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Food and Drug Administration","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Food and Drug Administration"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ FDA","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ FDA"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series D Financing","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Petrichor Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ FDA","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ FDA"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Divestment","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A||mTOR","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Whitehawk Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"||FK506-binding protein 1A","graph1":"Oncology","graph2":"Preclinical","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Eoc Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Collaboration","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.27000000000000002,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Eoc Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Eoc Pharma"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Foundation Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Foundation Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Foundation Medicine"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Acuta Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Acuta Capital Partners"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Aerpio Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Merger","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Aerpio Pharmaceuticals"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Avoro Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Avoro Capital","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Avoro Capital"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Whitehawk Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Whitehawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Whitehawk Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Whitehawk Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Insight","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emtora Biosciences \/ Cancer Insight","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Cancer Insight"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emtora Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Basel","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University Hospital, Basel","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Basel \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Basel \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dermatology Specialties Limited Partnership","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Dermatology Specialties Limited Partnership","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermatology Specialties Limited Partnership \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dermatology Specialties Limited Partnership \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AgelessRx","sponsor":"University of California, Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ University of California, Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ University of California, Los Angeles"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"North Texas Veterans Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ North Texas Veterans Healthcare System","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwestern Medical Center \/ North Texas Veterans Healthcare System"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A||Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santen Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Le Bonheur Children's Hospital","sponsor":"Pfizer Inc | University of Tennessee","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Le Bonheur Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Le Bonheur Children's Hospital \/ Pfizer Inc | University of Tennessee","highestDevelopmentStatusID":"6","companyTruncated":"Le Bonheur Children's Hospital \/ Pfizer Inc | University of Tennessee"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Peking University First Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Peking University First Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Peking University First Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Peking University First Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"9","companyTruncated":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Chinese SLE Treatment And Research Group","sponsor":"Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Chinese SLE Treatment And Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese SLE Treatment And Research Group \/ Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Chinese SLE Treatment And Research Group \/ Beijing Municipal Science & Technology Commission | North China Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Dongguan TT Medical","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Dongguan TT Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dongguan TT Medical \/ Peking University First Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Dongguan TT Medical \/ Peking University First Hospital"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Seoul National University Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Sinomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sinomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinomed \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sinomed \/ Undisclosed"},{"orgOrder":0,"company":"IHF Institut f\u00fcr Herzinfarktforschung","sponsor":"OrbusNeich","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"IHF Institut f\u00fcr Herzinfarktforschung","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IHF Institut f\u00fcr Herzinfarktforschung \/ OrbusNeich","highestDevelopmentStatusID":"11","companyTruncated":"IHF Institut f\u00fcr Herzinfarktforschung \/ OrbusNeich"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"Reliable Cancer Therapies | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Bergoni\u00e9 \/ Reliable Cancer Therapies | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Institut Bergoni\u00e9 \/ Reliable Cancer Therapies | Pfizer Inc"},{"orgOrder":0,"company":"Rare Partners srl","sponsor":"Universit\u00e0 degli Studi di Ferrara","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Rare Partners srl","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rare Partners srl \/ Universit\u00e0 degli Studi di Ferrara","highestDevelopmentStatusID":"8","companyTruncated":"Rare Partners srl \/ Universit\u00e0 degli Studi di Ferrara"},{"orgOrder":0,"company":"Universit\u00e0 degli Studi di Ferrara","sponsor":"Rare Partners srl | Meyer Children's Hospital | Azienda Ospedaliero, Universitaria Pisana","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Universit\u00e0 degli Studi di Ferrara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universit\u00e0 degli Studi di Ferrara \/ Rare Partners srl | Meyer Children's Hospital | Azienda Ospedaliero, Universitaria Pisana","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e0 degli Studi di Ferrara \/ Rare Partners srl | Meyer Children's Hospital | Azienda Ospedaliero, Universitaria Pisana"},{"orgOrder":0,"company":"Melanoma and Skin Cancer Trials Limited","sponsor":"Monash University | University of Queensland","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase III","graph3":"Melanoma and Skin Cancer Trials Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Melanoma and Skin Cancer Trials Limited \/ Monash University | University of Queensland","highestDevelopmentStatusID":"10","companyTruncated":"Melanoma and Skin Cancer Trials Limited \/ Monash University | University of Queensland"},{"orgOrder":0,"company":"Jena University Hospital","sponsor":"Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Jena University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital"},{"orgOrder":0,"company":"Jena University Hospital","sponsor":"Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Jena University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena","highestDevelopmentStatusID":"1","companyTruncated":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena"},{"orgOrder":0,"company":"InnoRa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"InnoRa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoRa \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"InnoRa \/ Undisclosed"},{"orgOrder":0,"company":"iVascular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"iVascular","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iVascular \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"iVascular \/ Undisclosed"},{"orgOrder":0,"company":"Pediatric Nephrology of Alabama","sponsor":"Pfizer Inc | The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Pediatric Nephrology of Alabama","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Pediatric Nephrology of Alabama \/ Pfizer Inc | The Emmes Company, LLC","highestDevelopmentStatusID":"1","companyTruncated":"Pediatric Nephrology of Alabama \/ Pfizer Inc | The Emmes Company, LLC"},{"orgOrder":0,"company":"TransDerm, Inc.","sponsor":"Pachyonychia Congenita Project","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"TransDerm, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Cream","sponsorNew":"TransDerm, Inc. \/ Pachyonychia Congenita Project","highestDevelopmentStatusID":"6","companyTruncated":"TransDerm, Inc. \/ Pachyonychia Congenita Project"},{"orgOrder":0,"company":"Stanford University","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stanford University \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Elixir Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Elixir Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Elixir Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Elixir Medical \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"National Institutes of Health | University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unity Health Toronto \/ National Institutes of Health | University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ National Institutes of Health | University of California, San Francisco"},{"orgOrder":0,"company":"London Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"London Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"London Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Pfizer Inc"},{"orgOrder":0,"company":"MaineHealth","sponsor":"Desmoid Tumor Research Foundation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaineHealth","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaineHealth \/ Desmoid Tumor Research Foundation | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"MaineHealth \/ Desmoid Tumor Research Foundation | Pfizer Inc"},{"orgOrder":0,"company":"Narrows Institute for Biomedical Research","sponsor":"Nobelpharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase II","graph3":"Narrows Institute for Biomedical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Narrows Institute for Biomedical Research \/ Nobelpharma","highestDevelopmentStatusID":"8","companyTruncated":"Narrows Institute for Biomedical Research \/ Nobelpharma"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Children's Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Boston Children's Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Ohio State University","sponsor":"PTEN Research | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University \/ PTEN Research | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Ohio State University \/ PTEN Research | Pfizer Inc"},{"orgOrder":0,"company":"University of Washington","sponsor":"Aadi Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ Aadi Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"University of Washington \/ Aadi Bioscience"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Nobelpharma America","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nobelpharma America \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nobelpharma America \/ Undisclosed"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Jena University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Jena University Hospital","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Jena University Hospital"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Terumo","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Collaboration","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Terumo","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Terumo"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"R3 Vascular","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"R3 Vascular","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"R3 Vascular \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"R3 Vascular \/ Undisclosed"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series A Financing","leadProduct":"Sirolimus","moa":"||FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Undisclosed"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Orchestra Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Orchestra Biomed \/ Undisclosed"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"The Emmes Company, LLC | Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Eye Institute \/ The Emmes Company, LLC | Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"National Eye Institute \/ The Emmes Company, LLC | Santen Pharmaceutical"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase III","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Cleveland Clinic \/ Pfizer Inc"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Neurology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"AI Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"AI Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AI Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AI Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Quoin Pharmaceuticals","sponsor":"University College Cork","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Quoin Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quoin Pharmaceuticals \/ University College Cork","highestDevelopmentStatusID":"4","companyTruncated":"Quoin Pharmaceuticals \/ University College Cork"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Cordis","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":1.1399999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":1.1399999999999999,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Cordis","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Cordis"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"Vascular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Vascular Therapies","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Vascular Therapies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vascular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Palvella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ligand Pharmaceuticals \/ Palvella Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ligand Pharmaceuticals \/ Palvella Therapeutics"},{"orgOrder":0,"company":"AgelessRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"AgelessRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgelessRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AgelessRx \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Financing","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Orchestra Biomed","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Orchestra Biomed \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NEW ZEALAND","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase II","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AFT Pharmaceuticals \/ Timber Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AFT Pharmaceuticals \/ Timber Pharmaceuticals"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Children's Healthcare of Atlanta","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Children's Healthcare of Atlanta","highestDevelopmentStatusID":"6","companyTruncated":"Gabrail Cancer Center Research \/ Children's Healthcare of Atlanta"},{"orgOrder":0,"company":"Phillip Freeman","sponsor":"Aarhus University Hospital | Odense University Hospital | OrbusNeich | Biosensors International","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Phillip Freeman","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phillip Freeman \/ Aarhus University Hospital | Odense University Hospital | OrbusNeich | Biosensors International","highestDevelopmentStatusID":"1","companyTruncated":"Phillip Freeman \/ Aarhus University Hospital | Odense University Hospital | OrbusNeich | Biosensors International"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":1.04,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||PGRN","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prevail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Advanced NanoTherapies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"||Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Advanced NanoTherapies","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Advanced NanoTherapies \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Advanced NanoTherapies \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Healx","sponsor":"Healx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Domatinostat","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healx \/ Vuja De Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Healx \/ Vuja De Sciences"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Palvella Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Anne Comi","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Anne Comi","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Anne Comi"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Helio Tedesco Silva Junior","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Helio Tedesco Silva Junior","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Helio Tedesco Silva Junior"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Sherif S. Farag","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Sherif S. Farag","highestDevelopmentStatusID":"7","companyTruncated":"Celgene Corporation \/ Sherif S. Farag"}]

Find Clinical Drug Pipeline Developments & Deals for Sirolimus

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Facial Angiofibroma.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          December 06, 2017

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Aucta Company Banner

                          02

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 20, 2014

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          03

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 20, 2014

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          04

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Qtorin (rapamycin) is a mTOR inhibitor currently being investigated in a range of rare genetic skin diseases, including angiokeratomas.

                          Product Name : Qtorin

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 24, 2025

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Under the agreement, Healx will aims to advance HLX-4310, an Investigational compounds being studied for the treatment of Osteosarcoma.

                          Product Name : HLX-4310

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 23, 2025

                          Lead Product(s) : Domatinostat,Sirolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Healx

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          CSPC ZhongQi

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          CSPC ZhongQi

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Sirolimus is a Antibiotic drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Gastro-enteropancreatic Neuroendocrine Tumor.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          September 10, 2025

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Orchestra BioMed secured strategic backing from Ligand and Medtronic to advance its lead programs, AVIM Therapy for hypertension and Virtue SAB delivering sirolimus for vascular disease.

                          Product Name : Virtue SAB

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          July 31, 2025

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $40.0 million

                          Deal Type : Financing

                          blank

                          08

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : The funding aims to advance the clinica development of comapany's late stage product Qtorin (sirolimus), which is being evaluated for the treatment of microcystic lymphatic malformations.

                          Product Name : Qtorin

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          June 09, 2025

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : FDA

                          Deal Size : $2.6 million

                          Deal Type : Funding

                          blank

                          09

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : The funding will be used to support registrational eRapa, a proprietary oral tablet formulation of rapamycin, phase 3 program in familial adenomatous polyposis.

                          Product Name : eRapa

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          May 22, 2025

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : CPRIT

                          Deal Size : $20.0 million

                          Deal Type : Funding

                          blank

                          10

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : eRapa, a proprietary encapsulated form of rapamycin, also known as sirolimus, is being developed for the treatment of familial adenomatous polyposis (FAP).

                          Product Name : eRapa

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 12, 2025

                          Lead Product(s) : Sirolimus

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank